A company that was serious would have also submitted to another regulatory agency such as FDA and EU. Again, the trial got over 4.5 years ago, but no guidance on US application. US is 20 X of UK in terms of revenue potential. US represents over 50% of the world’s revenue in oncology therapies.
One reason could be that they're understaffed and unable to handle both agencies at the same time. They might want to move forward with the next steps, thinking that MHRA approval will improve their chances with various agencies and approvals. One thing is certain: all of us—investors and patients—have lost out on the vaccine due to these delays.
Market Data 
Markets 
AI
